400 people in SA with highly drug-resistant TB to get new three-drug regimen

Treating highly drug-resistant forms of tuberculosis can take anything from nine to 24 months and patients have to contend with various unpleasant, and sometimes dangerous, side effects. A new six-month regimen made up of just three drugs that will be offered to 400 patients in South Africa might offer a better solution for some. Tiyese Jeranji reports.

Read More

COVID-19: How vaccine registration will work in SA

Before any COVID-19 vaccines can be made available in South Africa, they must be authorised by South Africa’s medicines regulator—the South African Health Products Regulatory Authority (SAHPRA). Catherine Tomlinson explores how SAHPRA is preparing to review and authorise the use of COVID-19 vaccines in the country and the different authorisation approaches they may use.

Read More

Finding the money: The case for raising the Health Promotion Levy

The recent budget policy statement shows South Africa finds itself in a very tight fiscal space where it has to navigate a global pandemic along with other health challenges such as rising rates of non-communicable diseases. Russell Rensburg argues that the Health Promotion Levy should be increased to 20% – which will raise much-needed revenue that will contribute to preventing disease and reducing healthcare costs.

Read More

What is behind SA’s higher TB numbers?

A World Health Organization report published last week showed more people are falling ill with tuberculosis in South Africa than previously thought – but also that the country’s treatment success rate for dangerous drug-resistant forms of the disease have improved. Amy Green asks what’s behind these numbers.

Read More

IN-DEPTH: The slow motion race for a TB vaccine

In recent months, the world has seen unprecedented investment in new vaccines. Yet, while a COVID-19 vaccine proven to be safe and effective may be less than a year away, a new tuberculosis vaccine might only be ready to be rolled out in a decade, despite a massive head start over COVID-19. Amy Green takes a closer look at the race for a new vaccine for the world’s top infectious disease killer.

Read More

1 3 4 5